These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30729252)

  • 1. Variation in bony landmarks and predictors of success with sacral neuromodulation.
    Husk KE; Norris LD; Willis-Gray MG; Borawski KM; Geller EJ
    Int Urogynecol J; 2019 Nov; 30(11):1973-1979. PubMed ID: 30729252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacral neuromodulation: sacral anatomy and optimal lead placement.
    Hendrickson WK; Amundsen CL
    Int Urogynecol J; 2021 Sep; 32(9):2545-2547. PubMed ID: 33237358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface and boney landmarks for sacral neuromodulation: a cadaveric study.
    Deveneau NE; Greenstein M; Mahalingashetty A; Herring NR; Lipetskaia L; Azadi A; Ostergard DR; Francis SL
    Int Urogynecol J; 2015 Feb; 26(2):263-8. PubMed ID: 25257811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
    Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
    Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacral neuromodulation: troubleshooting needle placement.
    Hendrickson WK; Amundsen CL
    Int Urogynecol J; 2021 Sep; 32(9):2549-2551. PubMed ID: 33416966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third sacral foramina morphometry for sacral neuromodulation.
    McCullough MC; Decker S; Ford J; Downes K; Hilbelink D; Ordorica R; Hoyte L; Hart S
    Female Pelvic Med Reconstr Surg; 2013; 19(1):23-30. PubMed ID: 23321655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human implantation of a mid-field powered neurostimulator at the sacral nerve: Results from an acute study.
    van Kerrebroeck PEVA; Reekmans M; van Koeveringe GA; Yeh AJ; Fayram TA; Sharan AD; Comiter CV
    Neurourol Urodyn; 2019 Aug; 38(6):1669-1675. PubMed ID: 31107559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for Difficult Fluoroscopic Landmarking During Sacral Neuromodulation Lead Placement.
    Luchristt D; Amundsen CL
    Urology; 2023 Apr; 174():218-220. PubMed ID: 36638971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
    Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
    World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is sensory testing during lead placement crucial for achieving positive outcomes after sacral neuromodulation?
    Peters KM; Killinger KA; Boura JA
    Neurourol Urodyn; 2011 Nov; 30(8):1489-92. PubMed ID: 21674596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacral neuromodulation using the standardized tined lead implantation technique with a curved vs a straight stylet: 2-year clinical outcomes and sensory responses to lead stimulation.
    Vaganée D; Kessler TM; Van de Borne S; De Win G; De Wachter S
    BJU Int; 2019 May; 123(5A):E7-E13. PubMed ID: 30537223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
    Kaaki B; Gupta D
    PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment.
    Marcelissen TA; Leong RK; Nieman FH; van Lankveld JJ; van Kerrebroeck PE; de Wachter SG
    BJU Int; 2011 Dec; 108(11):1834-8. PubMed ID: 21810157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study.
    Myer ENB; Petrikovets A; Slocum PD; Lee TG; Carter-Brooks CM; Noor N; Carlos DM; Wu E; Van Eck K; Fashokun TB; Yurteri-Kaplan L; Chen CCG
    Am J Obstet Gynecol; 2018 Jul; 219(1):78.e1-78.e9. PubMed ID: 29630890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Functional Outcomes of S3 Sacral Neuromodulation for the Treatment of Idiopathic Overactive Bladder.
    Ismail S; Chartier-Kastler E; Perrouin-Verbe MA; Rose-Dite-Modestine J; Denys P; Phé V
    Neuromodulation; 2017 Dec; 20(8):825-829. PubMed ID: 28967986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To stage or not to stage?-A cost minimization analysis of sacral neuromodulation placement strategies.
    Sun AJ; Harris CR; Comiter CV; Elliott CS
    Neurourol Urodyn; 2019 Aug; 38(6):1783-1791. PubMed ID: 31215706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cadaveric Study on the Efficacy of Surface Marking and Bony Landmarks Used in Sacral Neuromodulation.
    Almutairi S
    Cureus; 2020 Jul; 12(7):e9153. PubMed ID: 32676258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.